12.03
-0.33%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sunflower Pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 002737.SZ. It has been listed since 30 December 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.32bn and a net loss of CN¥257.8m. At that date it held total assets of CN¥5.33bn and shareholders' equity of CN¥3.84bn.
Sunflower Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and marketing of chemical medicines and health products. The company is headquartered in Harbin, Heilongjiang. The company went IPO on 2014-12-30. The firm provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Company’s main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Dec 2014
- Employees
- 5,278
- Website
- kuihuayaoye.com ↗
Leadership
Pay as last reported
- Ms. Yuxiu GuanChairman of the BoardCN¥1.2m
- Ms. Yi GuanDirector, General Manager(President)CN¥2.0m
- Ms. Chunhong WuFinance DirectorCN¥851,800
- Ms. Chao GuoDeputy General Manager(Vice President)
- Mr. Yang HaiDeputy General Manager(Vice President)CN¥193,800
- Mr. Yang YangDeputy General Manager, Director, since 2024
- Mr. Guangtao LiuDeputy General Manager
- Mr. Guangkuo ZhouSecretary of the Board
- Mr. Yanling GuanDirectorCN¥797,300
- Mr. Jingshang RenDirector, since 2022CN¥863,600
- Mr. Jianzhong ZhouDirector
- Mr. Jiajun MiaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sunflower Pharmaceutical Group employs 5,278 full-time employees in Harbin, Heilongjiang.
- The company offers six drug categories including digestive and pediatric medicines in China.
- Sunflower's main products like Weikangling capsules and pediatric Huatanzhike particles are well-established in domestic markets.
Weaknesses
- Sunflower Pharmaceutical Group has no international presence beyond China's domestic market.
- The company's product range is limited to six drug categories without expansion into new therapeutic areas.
- Sunflower's distribution is solely within China, lacking global market reach.
Opportunities
- Sunflower Pharmaceutical Group can expand into new therapeutic areas beyond current six drug categories.
- The domestic Chinese market offers growth potential for pharmaceutical companies like Sunflower.
- Sunflower could leverage its existing product portfolio to enter new domestic market segments.
Threats
- Sunflower Pharmaceutical Group faces competition from other domestic pharmaceutical firms in China.
- The Chinese pharmaceutical market is highly competitive with many established players.
- Sunflower's reliance on the domestic market exposes it to regulatory changes in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.